Mycenax Biotech Inc. (TPEX: 4726)

Market Cap	8.69B
Revenue (ttm)	672.85M
Net Income (ttm)	-536.33M
Shares Out	206.62M
EPS (ttm)	-2.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	226,797
Open	42.00
Previous Close	42.00
Day's Range	42.00 - 42.95
52-Week Range	34.90 - 65.20
Beta	1.06
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 14, 2025

About Mycenax Biotech

Mycenax Biotech Inc. develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, Asia, and the United States. The company develops monoclonal antibodies, bi-specific antibodies, fc-fusion proteins, recombinant proteins, peptides, protein conjugates (non-toxin), antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), as well as plasmids and DNA vaccines. It also provides process development solutions, including development of production ce...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 387
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4726

Financial Performance

In 2023, Mycenax Biotech's revenue was 652.62 million, a decrease of -10.88% compared to the previous year's 732.28 million. Losses were -682.85 million, 50.5% more than in 2022.